Daily notes / October 20, 2026

Robert Nelsen reported a City Therapeutics open-market purchase

Written by a model from the facts OQRO holds and checked against them, sentence by sentence of October 20, 2026. Published October 20, 2026. 3 min read.

High view of the New York Stock Exchange trading floor with its steel trusses, hanging screens, trading posts, flags and a crowd of traders below, and an NYSE banner on the far wall. — The New York Stock Exchange trading floor. Photo: Carol M. Highsmith, Public domain (donated by the photographer to the Library of Congress; no known restrictions). Original

The short answer

Robert Nelsen, a Director, reported buying 170,000 City Therapeutics shares at $18.00 each in an open-market transaction dated Oct 19, 2026. The Form 4 was filed on Oct 20, 2026, and reports an indirect holding of 13,692,507 shares after the purchase. The filing also reports an exercise or conversion of derivative securities on the transaction date.

What did Robert Nelsen report?

The SEC Form 4 reports an open-market purchase of 170,000 City Therapeutics (CTY) shares at $18.00 each, or about $3.06M. The transaction date was Oct 19, 2026, and the filing date was Oct 20, 2026, 1 day later.

The filing states that the shares are held indirectly. It puts the holding after the purchase at 13,692,507 shares, an increase of about 1.3% over the estimated holding before the transaction.

What other transaction appears on the same date?

The same person's filings also report an exercise or conversion of derivative securities dated Oct 19, 2026. The filing identifies the transaction code as M or C and reports that the Director exercised or converted 3.29M CTY derivative securities.

A Form 4 records transactions but does not say why they occurred. General background is that company trading windows may open after results, and sales can follow an option exercise, a tax bill or a pre-arranged plan. The filing does not establish which, if any, applies here.

How does this purchase compare with earlier filings?

OQRO holds no other open-market purchases by this person in the 365 days to Oct 20, 2026, and no earlier open-market purchase by this person in 12 months of their filings. Only 0 of this person's disclosed purchases have had 90 days since they were reported, too few for OQRO to show a result.

OQRO's insider records for City Therapeutics begin on Oct 20, 2026, so there is not enough history for a 12-month baseline. In the 90 days to Oct 20, 2026, 1 other open-market purchase, about $3.06M by 1 insider, was filed.

What other filings and coverage were on record?

The largest other filing of the same kind in that period was by ARCH Venture Partners XII, LLC, a 10% owner, for about $3.06M, filed Oct 20, 2026. The OQRO filing record lists that transaction.

Finnhub listed the SeekingAlpha headline “U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings”, dated Oct 17, 2026.

Finnhub also listed Yahoo headlines dated Oct 16, 2026: “City Therapeutics surges in market debut after upsizing $200M IPO” and “City Therapeutics Announces Pricing of Upsized Initial Public Offering”.

How did CTY shares trade around the transaction?

CTY closed at $21.46 on Oct 19, 2026, the last session on or before the trade date. From Oct 16, 2026 to Oct 19, 2026, the close moved from $22.40 to $21.46, a change of −4.2%.

These price moves are context only. The filing does not explain them, and other news can move a price. OQRO lists public insider records for City Therapeutics.

What this does not tell you?

A Form 4 reports a transaction; it does not say why it was made. Some purchases and sales follow trading windows or pre-arranged plans, and OQRO notes a plan only when a footnote of the filing says so. The filing does not identify which circumstances apply to this transaction.

Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise the articles. Comparisons use only the filings OQRO holds, and the available records do not provide enough history for a 12-month baseline or a result for purchases with 90 days elapsed.

This describes public filings. It is not investment advice.

Sources

A model wrote this page from the facts OQRO holds; every number, date, name and link in it was checked against those facts before publication, and a text that failed the check was not published. It describes what was filed, not why, and it is not investment advice. How OQRO treats data